John M. Hatcher

1.8k citations

33 papers · 967 indexed · h-index 16

Neurology top 10%
- Parkinson's Disease Mechanisms and Treatments 3
Organic Chemistry top 10%
Molecular Biology
- Protein Degradation and Inhibitors 13
- Ubiquitin and proteasome pathways 7
- Plant Gene Expression Analysis 3
Oncology
- Peptidase Inhibition and Analysis 5
Hematology
- Multiple Myeloma Research and Treatments 3
Cancer Research
- NF-κB Signaling Pathways 5
Genetics
- Chronic Lymphocytic Leukemia Research 4

Co-authors: Nathanael S. Gray Don M. Coltart Tinghu Zhang Hwan Geun Choi Mingxing Teng Dario R. Alessi Milka Kostić Jinwei Zhang
Cited by: Neurology Organic Chemistry Molecular Biology
Journals: ACS Medicinal Chemistry Letters (7 papers)Blood (4 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)
Partner nations: United States United Kingdom South Korea

In The Last Decade

John M. Hatcher

31 papers receiving 948 citations

Peers

Countries citing papers authored by John M. Hatcher

Since Specialization

Citations

This map shows the geographic impact of John M. Hatcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Hatcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Hatcher more than expected).

Fields of papers citing papers by John M. Hatcher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Hatcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Hatcher. The network helps show where John M. Hatcher may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John M. Hatcher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John M. Hatcher Line = papers co-authored together John M. Hatcher links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT, non-COVALENT and protacs targeting BTK in MYD88 mutated lymphomas. Blood ·Shirong Liu,Xia Liu,Amanda Kofides,John M. Hatcher,Nickolas Tsakmaklis,英二椎葉,B Faure,Seifolah Babaeian,Jinhua Wang,Maria Luisa Guerrera,Christopher J. Patterson,Zachary R. Hunter,Shayna Sarosiek,Jorge J. Castillo,Sara J. Buhrlage,A. Kossnchin	2025	0
2	Structure-guided design of a truncated heterobivalent chemical probe degrader of IRE1α RSC Medicinal Chemistry ·MA Hal,Yingpeng Liu,Jianwei Che,Katherine A. Donovan,John M. Hatcher,安洋福原,Cristiane Silva da Rocha,Radosław P. Nowak,Ronan de Oliveira Rocha,Tiffany Tsang,Eric S. Fischer,Lyn H. Jones	2025	1
3	ERK1/2 pro‐survival signalling is suppressed by pirtobrutinib in ibrutinib‐resistant MYD88‐mutated lymphoma cells British Journal of Haematology ·Manit Munshi,Xia Liu,Amanda Kofides,Nickolas Tsakmaklis,Zachary R. Hunter,Maria Luisa Guerrera,Christopher R. Schulz,Joshua Gustine,Shirong Liu,John M. Hatcher,Jie Chen,Kirsten Meid,Shayna Sarosiek,Catherine Flynn,Andrew R. Branagan,穆易,Lia Palomba,Jorge J. Castillo,Guang Yang,Steven P. Treon	2024	0
4	Development of a highly potent and selective degrader of LRRK2 Bioorganic & Medicinal Chemistry Letters ·John M. Hatcher,Jia Jhe Huang,Adil R. Sarhan,Xinzuo Huang,Francesca Tonelli,Dario R. Alessi,Paul Davies,Nathanael S. Gray	2023	12
5	Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions Journal of Medicinal Chemistry ·Yang Gao,Baishan Jiang,Y.M. Samir,Matthew J. Berberich,Jianwei Che,Katherine A. Donovan,John M. Hatcher,安洋福原,Nicholas Kwiatkowski,Yingpeng Liu,Verónica Franco,Cristiane Silva da Rocha,Qu Bin,Radosław P. Nowak,Tinghu Zhang,Eric S. Fischer,Nathanael S. Gray,Lyn H. Jones	2023	31
6	Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors Cancer Research ·Clare F. Malone,Shouyang Wang,Gabriela Alexe,Erdem Koçak,Christian Lindström,Amanda L. Robichaud,Amy Saur Conway,Amy Goodale,Michael G. Mwangi,Rubens Souza dos Santos,Allen Thayakumar,John M. Hatcher,Nathanael S. Gray,Federica Piccioni,Kimberly Stegmaier	2022	8
7	MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma Blood ·Neneng Era Wati,Lorena Fontán,Swain Jr.,David A. Scott,John M. Hatcher,Guangyan Du,Min Xia,Antonia Aleksieva,Nathanael S. Gray,Ari Melnick	2021	3
8	MALT1 DEGRADATION FOR THE TREATMENT OF ACTIVATED B‐CELL TYPE DIFFUSE LARGE B‐CELL LYMPHOMA Hematological Oncology ·Neneng Era Wati,Lorena Fontán,Juan 1821-1870 Rico y Amat,John M. Hatcher,Swain Jr.,Guocheng Du,Qi Qiao,Hao Wu,Antonia Aleksieva,Min Xia,Nathanael S. Gray,Ari Melnick	2021	1
9	Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation Cell chemical biology ·Tinghu Zhang,John M. Hatcher,Mingxing Teng,Nathanael S. Gray,Milka Kostić	2019	124
10	Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas Blood ·Lorena Fontán,John M. Hatcher,David A. Scott,Qi Qiao,Antonia Aleksieva,Guangyan Du,中間泰晴,R B Land,Hao Wu,Nathanael S. Gray,Ari Melnick	2019	5
11	Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor–associated kinase 4 (IRAK4) Journal of Biological Chemistry ·Li Wang,Ryan Ferrao,Qiubai Li,John M. Hatcher,Hwan Geun Choi,Sara J. Buhrlage,Nathanael S. Gray,Hao Wu	2019	13
12	Peptide-based covalent inhibitors of MALT1 paracaspase Bioorganic & Medicinal Chemistry Letters ·John M. Hatcher,Guangyan Du,Lorena Fontán,Antonia Aleksieva,Qi Qiao,Spandan Chennamadhavuni,یاسمن عرب عامری,Hao Wu,Ari Melnick,Nathanael S. Gray,David A. Scott	2019	13
13	Quinoline and thiazolopyridine allosteric inhibitors of MALT1 Bioorganic & Medicinal Chemistry Letters ·David A. Scott,John M. Hatcher,Hongyan Liu,Belal Alhuthaifi,Guangyan Du,Lorena Fontán,Antonia Aleksieva,Gabriella Casalena,Qi Qiao,Hao Wu,Ari Melnick,Nathanael S. Gray	2019	10
14	SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform Cell chemical biology ·John M. Hatcher,Guowei Wu,イン錫蔡,Jie Zhu,Meng Fan,Sherrina Patel,Wen‐qiu Wang,Scott B. Ficarro,Alan L. Leggett,Chelsea E. Powell,Jarrod A. Marto,Kang Zhang,Jacky Chi Ki Ngo,Xiang‐Dong Fu,Tinghu Zhang,Nathanael S. Gray	2018	96
15	Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8 ACS Medicinal Chemistry Letters ·John M. Hatcher,Eric S. Wang,Liv Johannessen,Nicholas Kwiatkowski,Taebo Sim,Nathanael S. Gray	2018	66
16	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth Journal of Clinical Investigation ·Lorena Fontán,Qi Qiao,John M. Hatcher,Gabriella Casalena,Antonia Aleksieva,Matt Teater,Brent E. Daniels,Guangyan Du,Min Xia,А.С. Попова,Spandan Chennamadhavuni,Giuseppe Palladino,Giorgio Inghirami,Ulrike Philippar,Hao Wu,David A. Scott,Nathanael S. Gray,Ari Melnick	2018	45
17	Small-Molecule Inhibitors of LRRK2 Advances in neurobiology ·John M. Hatcher,Hwan Geun Choi,Dario R. Alessi,Nathanael S. Gray	2017	27
18	Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer ACS Chemical Biology ·Hideki Terai,Li Tan,Ellen M. Beauchamp,John M. Hatcher,Qingsong Liu,Matthew Meyerson,Nathanael S. Gray,Peter S. Hammerman	2015	43
19	Discovery of a Pyrrolopyrimidine (JH-II-127), a Highly Potent, Selective, and Brain Penetrant LRRK2 Inhibitor ACS Medicinal Chemistry Letters ·John M. Hatcher,Jinwei Zhang,Hwan Geun Choi,Genta Ito,Dario R. Alessi,Nathanael S. Gray	2015	44
20	The Black Death Transformed: Disease and Culture in Early Renaissance Europe The English Historical Review ·John M. Hatcher	2003	16

About John M. Hatcher

John M. Hatcher is a scholar working on Oncology, Genetics, Hematology, Molecular Biology and Cancer Research, having authored 33 papers that have together received 967 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (7 papers), Peptidase Inhibition and Analysis (5 papers), NF-κB Signaling Pathways (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Multiple Myeloma Research and Treatments (3 papers), Parkinson's Disease Mechanisms and Treatments (3 papers) and Plant Gene Expression Analysis (3 papers). The work is most often cited by research in Neurology (144 citations), Organic Chemistry (252 citations), Molecular Biology (574 citations), Oncology (211 citations) and Hematology (63 citations). John M. Hatcher has collaborated with scholars based in United States, United Kingdom and South Korea. Frequent co-authors include Nathanael S. Gray, Don M. Coltart, Tinghu Zhang, Hwan Geun Choi, Mingxing Teng, Dario R. Alessi, Milka Kostić, Jinwei Zhang, Nicholas Kwiatkowski and Taebo Sim. Their work appears in journals such as ACS Medicinal Chemistry Letters, Blood, Bioorganic & Medicinal Chemistry Letters, Journal of Medicinal Chemistry and Cell chemical biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact